Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 2/2026

CO-PRESCRPTION OF ALLOPURINOL AND INDAPAMIDE IN CHRONIC PATIENTS

COSTEL GRIGORE 1, IRINA IONICĂ 1, VIOLETA POPOVICI 2*, WALTHER BILD 3, ROBERT ANCUCEANU 1, DUMITRU LUPULIASA 1, BRUNO ȘTEFAN VELESCU 1, TUDOR ION NĂSTĂSESCU 4

1 ”Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2 Center for Mountain Economics, ”Costin C. Kiritescu” National Institute of Economic Research (INCE-CEMONT), Romanian Academy, Vatra-Dornei, Romania
3 “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania
4 Tulcea County Emergency Hospital, Tulcea, Romania

Download Full Article PDF

This study aims to examine the concomitant use of indapamide and allopurinol in 1840 electronic health records (EHRs) from the health insurance system for patients aged 30 to 100 with chronic conditions as of January 2024. 509/1840 EHRs had inda- pamide, and 72/1840 had allopurinol; of the 72 EHRs with allopurinol, 31 contained it associated with indapamide. The rec- ommendation for allopurinol is strongly associated with indapamide use (p = 0.004) and with indapamide dose (p = 0.018), particularly with 1.5 mg (p = 0.003). Indapamide prescriptions are significantly associated with gender, age group, and allopu- rinol dose (p < 0.05). There was a significant association between gender and the daily allopurinol dose (chi2, p = 0.006). The present findings highlight the need to establish the true frequency of hyperuricemia with indapamide (currently listed as un- known in the current SmPCs), which is determined, on the one hand, by the large number of patients treated and, on the other hand, by the long-term consequences (renal damage and gout).